循环肿瘤DNA在胰腺癌诊治研究进展  

Role of circulating tumor DNA in diagnosis and treatment of pancreatic cancer:A literature review

作　　者：贾艳会[1,2,3] 杜双双 刘树业[1,2,3] JIA Yanhui;DU Shuangshuang;LIU Shuye(Clinical Laboratory of Tianjin Third Central Hospital,Tianjin 300170,China;Tianjin Key Laboratory of Artificial Cells,Tianjin 300170,China;Artificial Cell Engineering Technology Research Center of Ministry of Health,Tianjin 300170,China;不详)

机构地区：[1]天津市第三中心医院检验科,天津300170 [2]天津市人工细胞重点实验室,天津300170 [3]卫生部人工细胞工程技术研究中心,天津300170

出　　处：《实用医学杂志》2021年第7期948-952,共5页The Journal of Practical Medicine

摘　　要：胰腺癌是一种预后极差,严重威胁人类健康的恶性肿瘤。影像学、血清糖类抗原19-9(CA19-9)和组织活检等在胰腺癌的应用中都存在一定的局限性。循环肿瘤DNA(ctDNA)作为新兴的液体活检技术之一,因其标本采集的简便、非侵入性和实时反映肿瘤状态的特性,在胰腺癌的精准治疗中显示出巨大的应用前景。本文就ctDNA在胰腺癌的早期诊断、疾病分层、预测术后复发、纵向监测治疗反应及评估预后等应用进行综述,以期给科研和临床提供一些参考。Pancreatic cancer is a lethal malignancy with poor prognosis,and it is a serious threat to human health.Imaging examination,serum carbohydrate antigen 19-9(CA19-9)and tissue biopsy have some limitations in the diagnosis and treatment of pancreatic cancer.Circulating tumor DNA(ctDNA)is one of the newly emerging technologies for"liquid biopsy".It has shown promising clinical application in the precise treatment of pancreatic cancer due to its simple,non-invasive sampling and real-time monitoring of cancer burden.In the study,we reviewed the application of ctDNA in the early diagnosis of pancreatic cancer,disease stratification,prediction of postoperative recurrence,longitudinal monitoring of treatment response,hoping to provide some references for scientific research and clinical practice.

关 键 词：胰腺癌 液体活检 循环肿瘤DNA 精准医疗 

分 类 号：R735.9[医药卫生—肿瘤]